Oscar sells health plans to people who buy their own
2.69 million
members
18 states
over half its members in Florida
Exchange plans
almost all with a federal tax credit
Americans with no health cover through work buy plans on government-run marketplaces, almost all helped by a federal tax credit. Oscar sells those plans and pays its members' medical bills.
The company · 2 · What exactly does it sell?
Almost all of it is premiums
Each $1 of sales, 2025
98%2%0%
Premiums from membersInterest on its cashOther
Members, helped by the tax credit, pay monthly premiums; Oscar pays their claims out of them.
The company · 3 · How does it make money?
Premiums in, claims out, a thin slice kept
84.0%of premiums paid out in claims
14.2%of revenue spent on running costs
About 20%of direct premiums paid to rivals with sicker members
An insurer keeps what is left after claims and running costs, a few cents per dollar. Oscar also pays into a federal scheme that moves money to insurers with sicker members.
Is it a good business? · 4 · What gives it an edge?
Low cost wins members who compare every year
14.2%
running costs as a share of revenue
+46.2%
members in a shrinking market
About 30%
its share of its counties
But members won on price leave on price: they can switch plans every year.
Is it a good business? · 5 · What is the catch?
Rivals with sicker members get paid by Oscar
5.5 millionCentene's exchange members
$1.32Breceived by Florida Blue for 2025
$1.47Bpaid by Oscar's Florida insurer
Listed rivals: CNC · ELV · UNH
A rival with sicker members is paid partly out of Oscar's premiums.
Is it a good business? · 6 · What does its record show?
Growth made each member cheaper to serve
Sales, $B
1.8
4.0
5.9
9.2
11.7
17.5
Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025last 12 mo
Costs19.1% → 14.2%running costs per $1, 2024 to Q2 2026
Premiums$11.47Bpremiums in 2025
2025$396.4Mloss in 2025, after the risk payment
Running costs fall as members grow. The swings in profit come from claims and the risk payment, not from what growth costs.
Is it a good business? · 7 · How much room is there to grow?
A market of about $181B
About $181Bexchange premiums for 2026
22,973,219plan selections
12.9%Oscar's share
Nobody yet measures how large the part employers pay for will grow.
Is it a good business? · 8 · Who is in charge?
Aetna's former chief, with insiders holding the votes
April 2023Mark Bertolini chief executive
77.2%of votes held by insiders
About 2.45Mshares Bertolini sold under a plan
The company made its first profit under Bertolini. Most of the bonus rides on profit, premiums and running costs.
The story right now · 9 · Why do government credits matter so much?
A federal tax credit pays most members' premiums
About 97%of premiums with a tax credit
After 2025the extra credits expired
15 Januarythe 2027 sign-up season ends
Most Oscar members could not afford cover without the federal credit. When the extra credits expired, the market shrank, though Oscar still grew.
The story right now · 10 · Why is profit unknown until June?
A bill set by rivals' members, settled a year late
Oscar draws healthy membersLow prices win them.
Healthy members cost lessClaims look low.
The scheme evens it outOscar pays rivals.
The bill comes in JuneEvery quarter is an estimate.
In 2025 the risk payment turned a profit into a loss. Our question is how big 2026's will be.
The story right now · 11 · What changed lately?
Revenue rose 72%, and the year's forecast was raised
$5.1Brevenue, up 72%
84.0%claims share of premium, from 88.5%
$850M-$950M2026 operating profit forecast
2.69Mmembers, from 2.96M
Strong quarter
About $250M of revenue was a better estimate of what Oscar owes rivals, settled only in June 2027. The shares doubled in six months.
The story right now · 12 · What is everyone arguing about?
How big is 2026's bill to rivals?
Many investors think
2026 is a cycle top for the shares
We think
The year's profit turns on the risk payment, so fair
Every quarterly figure is an estimate until the June report. We are wrong if 2026's payment is at or below 20% of premium.
The price and our view · 13 · What is a share worth?
The price sits about a fifth below our value
$39.06what we think a share is worth · the last close is of that
$39.06our value
Attractive below $31.25
Neutral
Unattractive above $46.87
$28.35gloomy: profit per $1 falls to 2.8 cents
$39.06our estimate: fast growth, thin profit
$57.93sunny: growth runs a quarter faster
Value per share in three futures. None is a prediction of the share price.
We estimate what a share is worth from the cash the business should earn over many years. Our rule: buy only when the price is at least a fifth below our estimate, as a cushion for being wrong.
The price and our view · 14 · How could we be wrong?
Rivals' members set the bill
Rivals' members set the billBiggest
In 2025 it turned profit into loss.
The subsidy is the productWatch
Extra credits expired after 2025.
Members removed after the factShowing now
250,000 to 300,000 expected.
The 2026 billUnknown
Settled in June 2027.
$232M of first-half profit was earlier years' estimates reversing.
The price and our view · 15 · How will we know?
February shows the payment and the removals
A fourth-quarter loss inside $321M to $421MGood sign
A forecast cut below $800MBad sign
The 2026 risk payment above 21% of premiumWe turn negative
FEB 202710
Fourth-quarter 2026 results, February. Companies report every three months; each report is a test of the story.
Our view also changes on price alone: we turn positive if the shares fall a fifth below our estimate, and negative if they rise a fifth above it.
The price and our view · 16 · So, what do we think?
A low-cost insurer whose profit rivals' members set
$39.06our value
Attractive below $31.25
Neutral
Unattractive above $46.87
NeutralMedium conviction
Oscar runs cheaper than its rivals and took share of a shrinking market in 2026. But a federal scheme moving money to insurers with sicker members took about a fifth of its premiums. Neutral.
↑ ↓ to move · C for contents
What it does
More about the company
Who it is
Americans who get no health cover through work or the government can buy their own plan on the exchanges the Affordable Care Act set up. Oscar sells those plans: 2,042,449 members in 18 states at the end of 2025, more than half of them in Florida.
Almost every customer pays with help, since about 97% of 2025 premiums carried a federal tax credit. Its members skew younger and healthier than the market, and it runs on its own technology, with running costs down to 14.2% of revenue in Q2 2026.
How it makes money
Members, helped by their tax credits, pay a monthly premium, and Oscar keeps what is left after paying their doctors and hospitals and its own running costs. In 2025 premium was $11.47B of $11.70B of revenue; most of the rest was interest on the cash it holds. Because its members are healthier than average, Oscar must hand part of its premium to insurers with sicker members: about a fifth of it in the first half of 2026.
Growth and profit
What growth costs
For an insurer, growth costs running expenses and broker commissions, and here growing has made each member cheaper to serve: running costs fell as a share of revenue each year while revenue rose. The swings in profit come from claims and the risk-adjustment payment, not from what growth costs.
Its record
The numbers
Is it growing?Fast
Sales grew 55% over the twelve months to Sep 2026, faster than the 28% in the year to Dec 2025.
Is it profitable?Thin
Operating margin is 5.4%, up from −4.0% in the year to Dec 2023.
How steady is it?Swingy
Yearly sales growth has ranged from +28% to +297% over the last 5 years.
Does it earn good returns?Strong
Each dollar put into the business earns 41% a year after tax, up from 3.7% in the year to Dec 2024.
Is it making cash?Strong
It turned 24% of sales into free cash, $4.14B over the last twelve months.
Is the balance sheet safe?Net cash
It holds $7.49B of cash against $432M of debt, $7.06B more cash than it owes.
Are shares being diluted?Diluting
The share count rose 94% in 4.8 years, and pay in shares costs 0.4% of sales.
Why it wins
The evidence
Oscar's edge is cost. The tax credit is fixed against a benchmark plan, so a plan priced below it is cheaper for the member dollar for dollar, and members compare prices every year. Running costs of 14.2% of revenue let Oscar price low and still earn.
It worked in 2026. The exchanges shrank, by management's count about 12%, yet Oscar's members grew 46.2% and its share of the counties it serves roughly doubled to about 30%. But members won on price leave on price.
Who could beat it
The rivals in full
Its biggest rivals are Centene, the largest exchange insurer with 5.5 million members, and the local Blue Cross plans. In Florida, Oscar's largest state, Florida Blue received $1.32B from the risk-adjustment scheme for 2025 while Oscar's Florida insurer paid $1.47B: a rival with sicker members is paid partly out of Oscar's premiums.
Each rival
Centene Corporation (Ambetter Health)CNC
Sells the same exchange plans in 29 states and was the largest exchange insurer, with 5.5 million members at the end of 2025.
Florida Blueprivate
The Blue Cross plan in Florida, where 58% of Oscar's members are; it received $1.32B of risk-adjustment payments for 2025 while Oscar's Florida insurer paid $1.47B.
Elevance Health's Blue plansELV
Blue-licensed exchange plans in its own states, sold beside its employer, Medicaid and Medicare business.
Group health plans from the large insurers, such as UnitedHealth'sUNH
An employer keeps buying a group plan for its staff instead of giving them money to buy individual cover.
How big it could get
The market and who has signed
The market
The exchanges had 22,973,219 plan selections for 2026. At the roughly $7,900 a year Oscar collects per member, that is a market of about $181B, and Oscar's 2,963,002 members are 12.9% of it. Nobody yet measures how large the part employers pay for will grow, and this count leaves it out.
Who runs it
Leaders, pay and the cash
Who runs it
Mark Bertolini, who ran Aetna from 2010 to 2018, has been chief executive since April 2023, and the company made its first profit under him. Insiders and Thrive Capital control the votes: directors and officers hold 21.8% of the shares but 77.2% of the votes.
Most of the yearly bonus rides on operating margin, premiums and running costs. Bertolini bought 1,000,000 shares from the company in April 2026 and sold about 2.45M under a plan in June; co-founder Mario Schlosser sold 750,000 outside one in August.
What they did with the money
Oscar put $425.5M into its insurers in the first half of 2026 to back growth, $300M of it into a new Florida HMO. Its debt is $410M of convertible notes due 2030. Swapping other notes for about 30.8M shares in 2025 is part of why the share count rose 18.3% in a year.
The last report
The latest report
Oscar earned $178M from operations in Q3 and lifted its forecast
What it did to the thesis Strong quarter
The profit and the raise beat the test we set, and a better estimate of the payment to rivals supports the case. It is still an estimate, so the view stays Neutral.
The report
Q3 2026 revenue rose 72% to $5.1B and Oscar earned $178.0M from operations, against a $129.3M loss a year earlier. Claims took 84.0% of premium against 88.5%, running costs fell to 14.0% of revenue, and profit was $0.49 a share where analysts expected a loss. It raised its 2026 forecast for operating profit to $850M-$950M from $600M-$800M.
About $250M of the quarter's revenue was a better estimate of what Oscar owes rivals under the federal scheme, an estimate the government settles only in June 2027. Members fell to 2.69M from 2.96M in June, and the report does not say how many were removed.
What's happening now
The background
The tests continue. The 10-Q and call, due soon, should show how many members CMS removed and the payment's share of premium. The 2027 sign-up season runs from 1 November to 15 January, and CMS's June 2027 report settles 2026's risk-adjustment bill.
Where we disagree
Both sides in full
The market
2026 is a cycle top: the shares doubled, most analysts rate them hold or sell, and a second-half loss was expected.
We believe
The year's margin turns less on claims than on the risk-adjustment payment, set by rivals' members and settled a year late, so the shares are fair, not cheap.
The argument
The payment is published once a year, in CMS's June report, and every quarterly figure until then is an estimate. 2025's loss arrived exactly that way, at Centene as well as Oscar, when outside data showed the market sicker than expected.
We would be wrong if CMS's June 2027 report puts Oscar's 2026 payment at or below 20% of premium, with members above 2.6 million after removals. Then 2026's margin would look repeatable, and 18 times its profit would look low.
What it's worth
How we value it
Valued on the analysts' revenue path for three years, each later year closing 30% of the gap to 4%, on official operating profit with stock pay a cost and tax paid in full; the thesis's own evidence is the check on that path.
The three cases
Bear case$28.35
Growth follows the analysts' path, the margin settles a fifth lower at 2.8%, and new capital earns only the 8% rate: the downturn test. At this margin an added dollar of sales earns less than the rate on the capital it needs, so slower growth would be worth more; the test keeps the growth.
Our value$39.06
Revenue grows 16%, 16% and 28% over three years, the analysts' path (C59), then fades toward 4%, closing 30% of the gap each year; the margin moves to 3.5%, the analysts' year-three figure after stock pay; tax is 25%, the federal 21% plus state tax, the full rate once past losses are used up.
Bull case$57.93
Growth runs a quarter above the analysts' path, 20%, 20% and 36%, the margin reaches 3.8%, and new capital earns 11%.
The bet
Seen as a bet
The bet is that employers stop buying group cover and instead give workers money to buy their own plans, and that Oscar, which bought the platforms to sell them, wins a large slice. Management expects that market to grow several times over by 2029.
Even at the share Oscar targets, the profit is small beside the rest of the company, so success would move the price little. If it fails, shareholders keep most of what they own, because the exchange plans carry the value.
What could go wrong
Every risk
The risks
Rivals' members set the bill
If rivals' members prove sicker than Oscar's again, the risk-adjustment payment rises, as in 2025, when it helped turn a profit into a $396.4M loss.
The subsidy is the product
About 97% of premiums carried a federal tax credit. The enhanced credits expired after 2025, and any further cut shrinks the market Oscar sells into.
Members removed after the fact
CMS eligibility checks are expected to remove 250,000 to 300,000 members retroactively, and their premium is owed back rather than kept.
Members won on price leave
Oscar won 2026's members by being cheap, and members re-shop every year, so a rival pricing lower for 2027 can take them back.
Profit leans on old estimates
$232M of first-half profit was earlier years' estimates reversing, and the guide still implies a second-half loss of $142.7M to $242.7M.
Insiders hold the votes
Thrive Capital and the founders control most of the votes through 20-vote shares, so outside holders cannot change the board.
What we still do not know
How big Oscar's 2026 risk-adjustment bill really is, which CMS settles only in its June 2027 report.
How many members CMS's eligibility checks remove by the end of 2026, and whether they cost more than the guide assumes.
How many members Oscar's employer-paid plans have; the company does not report the number.
What changes our view
Every route to a new view
Every route to a new view
→ Attractive
The share price falls to about $31.25, 80% of what we think the business is worth.
→ Unattractive
The share price rises to about $46.87, 20% above what we think the business is worth.
→ Unattractive
The risk-adjustment payment rises above 21% of Oscar's direct premium for 2026. Oscar cuts its 2026 guide below $800M of profit from operations.
The next test
It supports the case if
The guide holds at $850M to $950M with the payment at or below 20% of direct premium, removals inside the 10-Q range and members above 2.6 million at year end.
It pressures the case if
The guide is cut back below $800M, the payment passes 21% of direct premium, or removals and year-end churn take members below 2.6 million.
We would also be wrong if
Retroactive removals run above 300,000 members, or members fall below 2.6 million by the end of 2026.
Oscar starts reporting its employer-paid members, and they pass 100,000 during 2027.
The verdict
Scores and how we weighed it
The scores
Growth
3 of 4
Business quality
2 of 4
Financial position
3 of 4
Execution record
2 of 4
Per share capture
2 of 4
Potential
2 of 4
Risk profile
2 of 4
Valuation
3 of 4
Evidence quality
3 of 4
How we weighed it
ValueMixed
The price sits just short of the margin of safety, close to the bear case.
BusinessNegative
Cheaper to run than rivals, but its profit depends on a federal transfer between insurers it cannot control.
GrowthMixed
Members grew in a shrinking market, but they were won on price and re-shop every year.
RisksNegative
The transfer owed to rivals may grow again, nearly all premiums rest on federal credits and regulators may remove members.
RivalsMixed
Rival insurers' sicker members set its bill, which no comparison of prices captures.
The groupMixed
It sits in none of our ranked groups; federal health policy moves it.
Latest newsPositive
The profit and the raised outlook beat our test; the payment to rivals is still an estimate.
In plain words
Risk adjustment
A federal scheme on the health exchanges. Insurers whose members are healthier than average pay into it, and those with sicker members are paid out of it, so no insurer wins just by attracting healthy people. The bill for a year is settled the following June.
In plain words
Our estimate of value
We forecast how much cash the business can earn over the next ten years and beyond, then ask what that stream is worth today to an investor who wants an 8% yearly return. We do it three times: a gloomy future, an expected one and a sunny one. We call a share Attractive only when its price is at least 20% below the expected estimate, and Unattractive when it is 20% above.